

Date: 7<sup>th</sup> May, 2025

To,  
The Manager,  
Department of Corporate Services,  
BSE Limited  
P. J. Towers, Dalal Street,  
Fort, Mumbai – 400 001  
Scrip Code: 533573

To,  
The Manager,  
Listing Department,  
National Stock Exchange of India Ltd.  
'Exchange Plaza', Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
NSE Symbol: APLLTD

Dear Sir/Madam,

**Sub: Disclosure under Regulation 30 and Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Publication of Audited Financial Results**

With reference to the captioned subject, we enclose herewith Newspaper cuttings of Extract of Audited Financial Results for the quarter and financial year ended 31<sup>st</sup> March, 2025, published in 'Economic Times, Indian Express, Business Standard and The Times of India (English Edition) and Divya Bhaskar and Financial Express (Gujarati Edition)' on 7<sup>th</sup> May, 2025.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,

**For Alembic Pharmaceuticals Limited**



**Manisha Saraf**  
Company Secretary

Encl.: A/a.

**ALEMBIC PHARMACEUTICALS LIMITED**

**ALEMBIC PHARMACEUTICALS LIMITED**

CIN: L24230GJ2010PLC061123

Regd. Office: Alembic Road, Vadodara - 390 003

Tel.: 0265 6637000

E-mail: apl.investors@alembic.co.in

Website: www.alembicpharmaceuticals.com

**Extract of statement of Consolidated Audited Financial Results  
for the quarter & year ended 31<sup>st</sup> March, 2025****(₹ in Crores except per share data)**

Particulars	Quarter Ended		Year Ended
	31.03.2025 (Audited)	31.03.2024 (Audited)	31.03.2025 (Audited)
Total Income from Operations	<b>1,769.64</b>	1,516.98	6,672.08
Net Profit for the period (before Tax, Exceptional and/ or Extraordinary items)	<b>191.95</b>	182.85	694.31
Net Profit for the period before tax (after Exceptional and/ or Extraordinary items)	<b>191.95</b>	182.85	707.18
Net Profit for the period after tax attributable to shareholders of the company (after Exceptional and/ or Extraordinary items)	<b>156.89</b>	178.21	583.42
Total Comprehensive Income for the period	<b>162.17</b>	166.70	587.54
Equity Share Capital	<b>39.31</b>	39.31	39.31
Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of previous year	—	—	5,151.63
Earning Per Share (Face Value of ₹2/- each) Basic & Diluted	<b>7.98</b>	9.07	29.68

**Notes:**

1. Standalone details	Quarter Ended		Year Ended
	31.03.2025 (Audited)	31.03.2024 (Audited)	31.03.2025 (Audited)
Income from Operations	<b>1,570.64</b>	1,474.55	6,032.63
Profit Before Tax	<b>91.56</b>	216.16	595.72
Profit After Tax	<b>75.34</b>	201.87	503.12

2. The above is an extract of the detailed format of the audited financial results filed with the Stock Exchanges. The detailed Financial Results are available on the Stock Exchange's website at [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com) and Company's website (URL: <https://alembicpharmaceuticals.com/quarterly-results>). The same can also be accessed by scanning the Quick Response (QR) Code provided below.

**For Alembic Pharmaceuticals Limited**

Sd/-

**Chirayu Amin****Chairman and CEO**

Place : Vadodara

Date : 6<sup>th</sup> May, 2025



**ALEMBIC PHARMACEUTICALS LIMITED**

CIN: L24230GJ2010PLC061123

Regd. Office: Alembic Road, Vadodara - 390 003

Tel.: 0265 6637000

E-mail: apl.investors@alembic.co.in

Website: www.alembicpharmaceuticals.com

**Extract of statement of Consolidated Audited Financial Results  
for the quarter & year ended 31<sup>st</sup> March, 2025**

(₹ in Crores except per share data)

Particulars	Quarter Ended		Year Ended
	31.03.2025 (Audited)	31.03.2024 (Audited)	31.03.2025 (Audited)
Total Income from Operations	1,769.64	1,516.98	6,672.08
Net Profit for the period (before Tax, Exceptional and/ or Extraordinary items)	191.95	182.85	694.31
Net Profit for the period before tax (after Exceptional and/ or Extraordinary items)	191.95	182.85	707.18
Net Profit for the period after tax attributable to shareholders of the company (after Exceptional and/ or Extraordinary items)	156.89	178.21	583.42
Total Comprehensive Income for the period	162.17	166.70	587.54
Equity Share Capital	39.31	39.31	39.31
Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of previous year	—	—	5,151.63
Earning Per Share (Face Value of ₹2/- each) Basic & Diluted	7.98	9.07	29.68

**Notes:**

1. Standalone details	Quarter Ended		Year Ended
	31.03.2025 (Audited)	31.03.2024 (Audited)	31.03.2025 (Audited)
Income from Operations	1,570.64	1,474.55	6,032.63
Profit Before Tax	91.56	216.16	595.72
Profit After Tax	75.34	201.87	503.12

2. The above is an extract of the detailed format of the audited financial results filed with the Stock Exchanges. The detailed Financial Results are available on the Stock Exchange's website at [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com) and Company's website (URL: <https://alembicpharmaceuticals.com/quarterly-results>). The same can also be accessed by scanning the Quick Response (QR) Code provided below.



For Alembic Pharmaceuticals Limited

Sd/-

Chirayu Amin

Chairman and CEO

Place : Vadodara

Date : 6<sup>th</sup> May, 2025

**ALEMBIC PHARMACEUTICALS LIMITED**

CIN: L24230GJ2010PLC061123

Regd. Office: Alembic Road, Vadodara - 390 003

Tel.: 0265 6637000

E-mail: apl.investors@alembic.co.in

Website: www.alembicpharmaceuticals.com

**Extract of statement of Consolidated Audited Financial Results  
for the quarter and year ended 31<sup>st</sup> March, 2025**

(₹ in Crores except per share data)

Particulars	Quarter Ended		Year Ended
	31.03.2025 (Audited)	31.03.2024 (Audited)	31.03.2025 (Audited)
Total Income from Operations	1,769.64	1,516.98	6,672.08
Net Profit for the period (before Tax, Exceptional and/ or Extraordinary items)	191.95	182.85	694.31
Net Profit for the period before tax (after Exceptional and/ or Extraordinary items)	191.95	182.85	707.18
Net Profit for the period after tax attributable to shareholders of the company (after Exceptional and/ or Extraordinary items)	156.89	178.21	583.42
Total Comprehensive Income for the period	162.17	166.70	587.54
Equity Share Capital	39.31	39.31	39.31
Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of previous year	—	—	5,151.63
Earning Per Share (Face Value of ₹2/- each) Basic & Diluted	7.98	9.07	29.68

**Notes:**

1. Standalone details	Quarter Ended		Year Ended
	31.03.2025 (Audited)	31.03.2024 (Audited)	31.03.2025 (Audited)
Income from Operations	1,570.64	1,474.55	6,032.63
Profit Before Tax	91.56	216.16	595.72
*Profit After Tax	75.34	201.87	503.12

2. The above is an extract of the detailed format of the audited financial results filed with the Stock Exchanges. The detailed Financial Results are available on the Stock Exchange's website at [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com) and Company's website (URL: <https://alembicpharmaceuticals.com/quarterly-results>). The same can also be accessed by scanning the Quick Response (QR) Code provided below.



For Alembic Pharmaceuticals Limited

Sd/-

Chirayu Amin

Chairman and CEO

Place : Vadodara

Date : 6<sup>th</sup> May, 2025



## ALEMBIC PHARMACEUTICALS LIMITED

CIN: L24230GJ2010PLC061123

Regd. Office: Alembic Road, Vadodara - 390 003

Tel.: 0265 6637000

E-mail: apl.investors@alembic.co.in

Website: www.alembicpharmaceuticals.com

### Extract of statement of Consolidated Audited Financial Results for the quarter & year ended 31<sup>st</sup> March, 2025

(₹ in Crores except per share data)

Particulars	Quarter Ended		Year Ended
	31.03.2025 (Audited)	31.03.2024 (Audited)	31.03.2025 (Audited)
Total Income from Operations	1,769.64	1,516.98	6,672.08
Net Profit for the period (before Tax, Exceptional and/ or Extraordinary items)	191.95	182.85	694.31
Net Profit for the period before tax (after Exceptional and/ or Extraordinary items)	191.95	182.85	707.18
Net Profit for the period after tax attributable to shareholders of the company (after Exceptional and/ or Extraordinary items)	156.89	178.21	583.42
Total Comprehensive Income for the period	162.17	166.70	587.54
Equity Share Capital	39.31	39.31	39.31
Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of previous year	—	—	5,151.63
Earning Per Share (Face Value of ₹2/- each) Basic & Diluted	7.98	9.07	29.68

#### Notes:

1. Standalone details	Quarter Ended		Year Ended
	31.03.2025 (Audited)	31.03.2024 (Audited)	31.03.2025 (Audited)
Income from Operations	1,570.64	1,474.55	6,032.63
Profit Before Tax	91.56	216.16	595.72
Profit After Tax	75.34	201.87	503.12

2. The above is an extract of the detailed format of the audited financial results filed with the Stock Exchanges. The detailed Financial Results are available on the Stock Exchange's website at [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com) and Company's website (URL: <https://alembicpharmaceuticals.com/quarterly-results>). The same can also be accessed by scanning the Quick Response (QR) Code provided below.



For Alembic Pharmaceuticals Limited

Sd/-

Chirayu Amin  
Chairman and CEO

Place : Vadodara  
Date : 6<sup>th</sup> May, 2025



**ALEMBIC PHARMACEUTICALS LIMITED**

CIN: L24230GJ2010PLC061123

Regd. Office: Alembic Road, Vadodara - 390 003

Tel.: 0265 6637000

E-mail: apl.investors@alembic.co.in

Website: www.alembicpharmaceuticals.com

**Extract of statement of Consolidated Audited Financial Results  
for the quarter & year ended 31<sup>st</sup> March, 2025**

(₹ in Crores except per share data)

Particulars	Quarter Ended		Year Ended
	31.03.2025 (Audited)	31.03.2024 (Audited)	31.03.2025 (Audited)
Total Income from Operations	1,769.64	1,516.98	6,672.08
Net Profit for the period (before Tax, Exceptional and/ or Extraordinary items)	191.95	182.85	694.31
Net Profit for the period before tax (after Exceptional and/ or Extraordinary items)	191.95	182.85	707.18
Net Profit for the period after tax attributable to shareholders of the company (after Exceptional and/ or Extraordinary items)	156.89	178.21	583.42
Total Comprehensive Income for the period	162.17	166.70	587.54
Equity Share Capital	39.31	39.31	39.31
Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of previous year	—	—	5,151.63
Earning Per Share (Face Value of ₹2/- each) Basic & Diluted	7.98	9.07	29.68

**Notes:**

1. Standalone details	Quarter Ended		Year Ended
	31.03.2025 (Audited)	31.03.2024 (Audited)	31.03.2025 (Audited)
Income from Operations	1,570.64	1,474.55	6,032.63
Profit Before Tax	91.56	216.16	595.72
Profit After Tax	75.34	201.87	503.12

2. The above is an extract of the detailed format of the audited financial results filed with the Stock Exchanges. The detailed Financial Results are available on the Stock Exchange's website at [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com) and Company's website (URL: <https://alembicpharmaceuticals.com/quarterly-results>). The same can also be accessed by scanning the Quick Response (QR) Code provided below.



For Alembic Pharmaceuticals Limited

Sd/-

Chirayu Amin

Chairman and CEO

Place : Vadodara

Date : 6<sup>th</sup> May, 2025

**TATA ELXSI LIMITED**  
 CIN : L55110KA1989PL0009968  
 Registered & Corporate Office:  
 ITPB Road, Whitefield, Bengaluru - 560048  
 Tel: 080 2297 9123  
 E-mail: investors@tataelxsi.com Website: www.tataelxsi.com

**TRANSFER OF EQUITY SHARES TO INVESTOR EDUCATION AND PROTECTION FUND NOTICE**

NOTICE is hereby given that pursuant to Section 124 of the Companies Act, 2013 ('the Act') and the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules 2016 ('the Rules') as amended to date, the equity shares of the Company in respect of which dividend amounts have remained unclaimed for seven consecutive years or more are required to be transferred to the Investor Education and Protection Fund (IEPF).

Accordingly, the Company has communicated to the respective shareholders vide its reminder letter dated May 06, 2025, to all the concerned shareholders, whose shares are liable to be transferred to IEPF during FY 2025-26 and requesting them to claim such unclaimed/unpaid dividend(s) from FY 2017-18 till date, on or before August 08, 2025. The details of such unpaid/unclaimed dividend (s) as prescribed under the IEPF Rules have been placed on the website of the Company - www.tataelxsi.com under Investor Section. We request those concerned shareholders to claim their unclaimed/unpaid dividend(s), by making an application immediately to MUFG Intime India Private Limited, (formerly Link Intime India Private Limited) Registrar and Transfer Agent of the Company.

In case, the dividend amount(s) is not claimed on or before August 08, 2025, the Company will transfer the unclaimed dividend amount for FY 2017-18 to IEPF and consequently transfer the shares held by concerned shareholders to IEPF, without any further notice, by following the due process as provided under the IEPF Rules. Shareholders may kindly note that subsequent to such transfer of relevant shares to IEPF, all future benefits which may accrue thereunder, including future dividends, if any, will be credited to IEPF.

Further, shareholders may kindly note that, after the above-referred transfer is made, refunds from IEPF can be claimed only by complying with the provisions of Rule 7 of the said rules. Please note that no claim can be made against the Company in respect of shares/dividends transferred to IEPF under the said IEPF Rules.

Shareholders are encouraged to furnish / update their PAN, KYC details including contact details & bank account details. Nomination and specimen signature with the RTA / the Company in specified forms, as mandated by the Securities and Exchange Board of India ("SEBI"). The detailed instructions to update PAN, KYC details including contact details & bank account details, Nomination and specimen signature with the RTA / the Company are provided in the intimation sent to the shareholders. Shareholders are requested to refer the same to update their PAN, KYC and Nomination details.

In case the shareholders have any queries on the subject matter, they may contact the Company's Registrar and Transfer Agent, MUFG Intime India Private Limited, C-101, 1st Floor, 247 Park, Lal Bahadur Shastri Marg, Vikhroli (West), Mumbai 400 083 Tel No.: +91-8108118484.

For raising queries, please visit the website: www.in.mpms.mufg.com under the Menu Item 'Investor Services - Service Request'

for TATA ELXSI LIMITED  
 Sd/-  
 Cauveri Sriram  
 Company Secretary & Compliance Officer

Place : Bengaluru  
 Dated : May 06, 2025

**Alembic એલેમ્બિક ફાર્માસ્યુટિકલ્સ લિમિટેડ**  
 CIN: L24230GJ2010PLC061123  
 રજીસ્ટર્ડ ઓફિસ: એલેમ્બિક રોડ, વડોદરા-૩૬૦ ૦૦૩  
 ફોન : +૯૧ ૦૨૨૫-૬૬૩૭૦૦૦  
 ઈ-મેલ : apl.investors@alembic.co.in  
 વેબસાઇટ : www.alembicpharmaceuticals.com

**નોટીસ**  
**(કંપનીના ઇન્વેસ્ટર શેર્સ ઇન્વેસ્ટર એજ્યુકેશન એન્ડ પ્રોટેક્શન ફંડ (IEPF) માં તબદિલ કરવા બાબત)**

આ નોટીસ ઇન્વેસ્ટર એજ્યુકેશન એન્ડ પ્રોટેક્શન ફંડ ઓથોરિટી (એકાઉન્ટિંગ, ઓડિટ, ટ્રાન્સફર એન્ડ રીફંડ) રૂલ્સ, ૨૦૧૬ અન્વયે પ્રસિદ્ધ કરવામાં આવી છે. આ નિયમોમાં, અન્ય બાબતો ઉપરાંત, એવા બંધા જ શેર્સ જેના ઉપર સતત સાત વર્ષો સુધી ડીવીડન્ડ ચૂકવવાનું નથી કે શેરધારક દ્વારા માંગણી કરાઈ નથી તે ઇન્વેસ્ટર એજ્યુકેશન એન્ડ પ્રોટેક્શન ફંડ (IEPF) નાં ડીમેટ ખાતામાં ટ્રાન્સફર કરવાની જોગવાઈ છે.

નિયમોમાં નિર્ધારિત વિવિધ આવશ્યકતાઓનું પાલન કરતા, કંપનીએ જેમના શેર આ નિયમો અન્વયે IEPF ડીમેટ ખાતામાં ટ્રાન્સફર કરવા પાત્ર થાય છે તે લાગતા વળગતા બંધા જ શેરધારકોને તેમના કંપની પાસે ઉપલબ્ધ સરનામાં પર વ્યક્તિગત રીતે ચોક્કસ કાર્યવાહી કરવા જાણ કરી છે.

કંપનીએ આવા શેરધારકોની વિગતો જેવી કે નામ અને ફોલીઓ નંબર/ ડીપી આઈડી, ક્લાયન્ટ આઈડી નીચે દર્શાવેલ વેબસાઇટ ઉપર મુકેલ છે:  
<https://alembicpharmaceuticals.com/iepf>  
 માંગણી નહી કરાવેલ ડીવીડન્ડની વિગતો નીચે દર્શાવેલ વેબસાઇટ પર ઉપલબ્ધ છે:  
<https://alembicpharmaceuticals.com/unpaid-unclaimed-dividend>

શેરધારકોને વિનંતી કરવામાં આવે છે કે તેઓ વિગતોને ચકાશો અને તેમના માંગણી નહી કરાવેલ ડીવીડન્ડનો દાવો તરત જ કરે.

જેમના શેર્સ IEPF ડીમેટ ખાતામાં ટ્રાન્સફર થવા પાત્ર છે તેવા શેરધારકોએ નોંધ લેવી કે તેમના શેર્સ ડી-ડીકલેટ કે ઇલેક્ટ્રોનિક ફોર્મમાં, નિયમોમાં આપેલ કાર્યપદ્ધતિ પ્રમાણે IEPF ડીમેટ ખાતામાં ટ્રાન્સફર કરવામાં આવશે. ડી-ડીકલેટ ફોર્મમાં શેર્સ ધરાવતા શેરધારકોના સંદર્ભમાં, IEPF ના ડીમેટ ખાતામાં શેર્સના સ્થાનાંતરણ પછી, તેમના નામ પર નોંધાયેલા મૂળ શેર સર્ટિફિકેટો આપોઆપ રદ થઈ જશે અને બિન વાટાઘાટપાત્ર (બિન - નેગોશિયેબલ) માનવામાં આવશે. ડીમેટ ફોર્મમાં શેર્સ ધરાવતા શેરધારકોના સંદર્ભમાં, કંપની તેમના ખાતામાં રહેલા શેર્સ ને IEPF ડીમેટ ખાતાની તરફથી ટ્રાન્સફર કરવા માટે કોર્પોરેટ એક્શન દ્વારા સંબંધિત ડિપોઝિટરી ને જાણ કરશે.

શેરધારકોએ વધુમાં નોંધ લેવી કે કંપનીએ પોતાની વેબસાઇટ ઉપર મુકેલી વિગતો કંપની દ્વારા આ નિયમો અનુસાર નવા શેર સર્ટિફિકેટ જારી કરવા અને IEPF ડીમેટ ખાતામાં ટ્રાન્સફર કરવા માટે પૂરતી નોટિસ તરફી ગણાશે.

જો ૧૦મી ઓગસ્ટ, ૨૦૨૫ અથવા કંપની દ્વારા લંબાવવામાં આવેલી અન્ય તારીખ સુધીમાં સંબંધિત શેર ધારકો તરફથી કોઈ સુચના પ્રાપ્ત નથી થાય તો નિયમોમાં કાર્યવાહી અનુપાલનમાં આ શેર્સ નિયત તારીખે તે નિયમોમાં આપેલી કાર્યપદ્ધતિ પ્રમાણે કંપનીની કોઈપણ પ્રકારની આગળની કાર્યવાહી અથવા જવાબદારી વગર IEPF ડીમેટ ખાતામાં ટ્રાન્સફર કરવામાં આવશે.

શેર ધારકોએ નોંધ લેવી કે IEPF માં ટ્રાન્સફર થયેલા, ન ચૂકવાયેલા ડીવીડન્ડ અને શેર્સ અને તેમની ઉપર મળી શકતા બંધા લાભો, જો કોઈ હોય તો, સહીત નિયમ પ્રમાણેની કાર્યપદ્ધતિ મુજબ IEPF ઓથોરિટી પાસેથી વેબ ફોર્મ IEPF-5 ભરીને પરત મેળવી શકાશે.

જો શેરધારકોને આ વિષયમાં કે નિયમો અંગે કોઈ પ્રશ્ન હોય તો તેઓ કંપનીના રજીસ્ટ્રાર અને શેર ટ્રાન્સફર એજન્ટ્સ, MUFG ઇન્ટાઇમ ઇન્ડિયા પ્રા. લી., "ગીતાકુંજ" ૧, ભક્તિનગર સોસાયટી, એનીએસ ટાવરની પાછળ, જુના પાદરા રોડ, વડોદરા-૩૬૦ ૦૧૫, ગુજરાત. ફોન નં.: +૯૧ ૨૨૫ ૩૫૬૭૭૮ ઈ-મેલ : vadodara@in.mpms.mufg.com નો સંપર્ક કરી શકે છે.

**એલેમ્બિક ફાર્માસ્યુટિકલ્સ લિમિટેડ વતી,**  
 સહી / -  
**મનીષા સરાઈ**  
 તારીખ : ૬મી મે, ૨૦૨૫  
 કંપની સેક્રેટરી

સ્થળ : વડોદરા  
 તારીખ : ૬મી મે, ૨૦૨૫



**Extract of Audited Consolidated Financial Results for the Quarter and Year ended 31 March 2025**  
 (₹ in crores, except per share data)

Sr. No.	Particulars	Quarter ended			Year ended	
		31 March 2025 (Audited)	31 December 2024 (Unaudited)	31 March 2024 (Audited)	31 March 2025 (Audited)	31 March 2024 (Audited)
1	<b>Income</b>					
	a) Revenue from operations	1,221.85	1,155.62	1,208.17	4,635.07	4,474.03
	b) Other income	12.46	10.30	17.42	42.74	46.20
2	Profit before share of loss from joint venture, exceptional items and tax	101.40	116.60	143.02	483.49	588.16
3	Net Profit for the period before Tax, Exceptional and/or Extraordinary items	108.39	115.60	142.32	484.26	586.96
4	Net Profit for the period before Tax from continuing operations (after Exceptional and/or Extraordinary items)	108.39	115.60	142.32	484.26	586.96
5	Profit for the period/ year from continuing operations	73.97	84.87	106.95	348.31	443.50
6	Net Profit from discontinued operations	(30.79)	(5.89)	(2.68)	(48.29)	(11.34)
7	Net Profit for the period (Continuing and discontinued operations)	43.18	78.98	104.27	300.02	432.16
8	Total comprehensive income for the period [Comprising Profit for the period (after tax), Other comprehensive income (after tax) and after non controlling interests]	43.12	78.13	103.02	295.53	422.26
9	Equity share capital (Face value of Re 1/- per share)	15.93	15.93	15.93	15.93	15.93
10	Other equity (excluding revaluation reserve) as shown in the audited balance sheet of the previous year.				2,728.41	2,600.60
11	Earnings per equity share (EPS); (face value : ₹ 1 per share) (EPS for the quarters/periods is not annualised) For continuing and discontinued operations					
	a) Basic (₹)	2.67	4.88	6.43	18.48	26.51
	b) Diluted (₹)	2.67	4.88	6.43	18.47	26.48

**Notes:**

- The above consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 6 May 2025. The statutory auditors have expressed an unmodified audit opinion on these results.
- The above results have been prepared in accordance with the Indian Accounting Standards ('Ind-AS') as notified under the Companies (Indian Accounting Standards) Rules, 2015 (as amended), specified under section 133 of the Companies Act, 2013.
- The Board of Directors approved to discontinue the operations of Kajaria Plywood Private Limited (KPPL), a wholly owned subsidiary of the Company due to lack of strategic fit and continued losses. The related incomes and expenses have been disclosed under discontinued operations.
- The Board of Directors have recommended a final dividend of ₹4/- per equity share of face value of ₹1/- each for the financial year ended 31 March 2025 subject to the approval of the shareholders in the ensuing Annual General Meeting. During the year, the Company has paid Interim Dividend of ₹5/- per equity share aggregating to ₹79.63 crores thereby making the total dividend of ₹9/- per share (previous year ₹12/- per share) aggregating to ₹143.34 crores.
- Additional information on standalone financial results is as follows:**

(₹ in crores)

Sr. No.	Particulars	Quarter ended			Year ended	
		31 March 2025 (Audited)	31 December 2024 (Unaudited)	31 March 2024 (Audited)	31 March 2025 (Audited)	31 March 2024 (Audited)
1	<b>Income</b>					
	a) Revenue from operations	1,104.93	1,049.65	1,104.11	4,218.82	4,103.02
	b) Other income	17.40	17.03	24.27	67.85	68.56
2	Net Profit before tax	(29.26)	106.91	126.86	319.25	512.24
3	Net Profit after tax	(54.88)	79.55	95.23	204.14	381.45
4	Total comprehensive income for the period	(54.44)	79.62	95.59	204.80	381.38

The above is an extract of the detailed format of Financial Results for the quarter and year ended 31 March 2025 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. The full format of the Standalone and Consolidated Financial Results are available on the website of BSE and NSE at www.bseindia.com and www.nseindia.com respectively and on the Company's website at <https://www.kajariaceramics.com/pdf/financialResults/Q4-24-25.pdf> and can also be accessed by scanning the Quick Response Code given below.

For and on behalf of the Board  
**Ashok Kajaria**  
 Chairman & Managing Director

Place: New Delhi  
 Date: 6 May 2025

**KAJARIA CERAMICS LIMITED**  
 Regd Office: SF-11, Second Floor, JMD Regent Plaza, Mehrauli-Gurgaon Road, Village Sikanderpur Ghosi, Gurgaon -122001 (Haryana)  
 Corporate Office: J-1/B-1 (Extn), Mohan Co-operative Industrial Estate, Mathura Road, New Delhi -110044, Ph: 91-11-26946409  
 Fax: 91-11-26949544, 91-11-26946407  
 CIN: L26924HR1985PLC056150, E-mail: investors@kajariaceramics.com, Website: www.kajariaceramics.com

**JASH ENGINEERING LIMITED**  
 CIN:L28910MP1973PLC001226

RODNEY HUNT Since 1840  
 MAHR MASCHINENBAU GMBH, AUSTRIA Since 1927  
 WATERFRONT Since 2006  
 WATERFRONT FLUID CONTROLS LTD, UK

Equipment for water & wastewater conveyance, pumping & treatment

43% Revenue Growth  
 30% PAT Growth  
 26% EPS Growth  
 63% Revenue Out of India  
 838 Cr Order Book Position

**EXTRACT OF THE AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31<sup>ST</sup> MARCH 2025**

Sr. No.	Particulars (In Lakhs Except for EPS)	Quarter Ended			Year Ended	
		31-Mar-2025 Unaudited	31-Dec-2024 Unaudited	31-Mar-2024 Unaudited	31-Mar-2025 Audited	31-Mar-2024 Audited
1	Total Income from operations	30341.75	18201.63	21872.84	74556.04	52196.68
2	Net Profit / (Loss) for the period before Tax	5090.97	3471.67	4884.22	10763.67	8322.58
3	Net Profit / (Loss) for the period after tax	3575.04	3479.72	3895.45	8676.94	6676.92
4	Total Comprehensive Income for the period	3675.12	3397.61	3919.99	8816.66	6763.13
5	Paid-up Equity Share capital (Face value per share Rs.2/- each)	1255.10	1251.25	1237.64	1255.10	1237.64
6	<b>Earning per share</b>					
	a) Basic (not annualised)	5.72	5.54	6.46	13.88	11.07
	b) Diluted (not annualised)	5.68	5.50	6.37	13.78	10.91

**EXTRACT OF THE AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31<sup>ST</sup> MARCH 2025**

Sr. No.	Particulars (In Lakhs Except for EPS)	Quarter Ended			Year Ended	
		31-Mar-2025 Unaudited	31-Dec-2024 Unaudited	31-Mar-2024 Unaudited	31-Mar-2025 Audited	31-Mar-2024 Audited
1	Total Income from operations	17938.25	10367.19	14084.02	48400.67	35258.04
2	Net Profit / (Loss) for the period before Tax	2489.01	1977.04	2750.51	8516.81	6004.56
3	Net Profit / (Loss) for the period after tax	1909.43	1655.60	2265.27	6906.84	5011.87
4	Total Comprehensive Income for the period	1902.78	1601.31	2261.77	6737.30	4921.24
5	Paid-up Equity Share capital (Face value per share Rs.2/- each)	1255.10	1251.25	1237.64	1255.10	1237.64
6	<b>Earning per share</b>					
	a) Basic (not annualised)	3.05	2.64	3.76	11.05	8.31
	b) Diluted (not annualised)	3.03	2.62	3.70	10.97	8.19

The above audited and consolidated financial results of Jash Engineering Limited ("the Company" or "the Holding Company") and the Group comprising its Subsidiaries and Joint Venture, for the quarter and year ended 31st March 2025 have been reviewed by the Audit Committee and approved by the Board of Directors of the Holding Company in their respective meetings held on 5th May 2025. The statutory auditors have conducted audit of these financial results in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and have expressed an unmodified opinion on the audited standalone and consolidated financial results for the quarter and year ended 31st March 2025. The full format of the statement of Standalone and Consolidated Financial Results are available on the website of the National Stock Exchange of India Limited, [www.nseindia.com](http://www.nseindia.com) and on the Company's website, [www.jashindia.com](http://www.jashindia.com).

Reg Office: 31, Sector-C, Sanwer Road, Industrial Area, Indore 452015, MP, INDIA  
 Ph: 0731-6732700  
 Email: info@jashindia.com  
 Website: www.jashindia.com

For, Jash Engineering Limited  
 Pratik Patel  
 Chairman & Managing Director  
 DIN - 00780920

Contributing to a sustainable environment ..... Worldwide !

**Is your opinion yours?**

Your opinion should belong to you.  
 A voice that is your own.  
 Undeterred. Uncompromised. And brave.  
 A conscience that isn't at peace, until the truth is uncovered.  
 A mind that isn't fuelled by someone else's thoughts.  
 Where actions are based on informed opinions and not ignorant assumptions.

Because it's not about going where everyone goes.  
 Or being part of a trend because it is one.  
 Or taking sides because you don't know enough.

It's about freedom.  
 The freedom to have an opinion that's yours.

At Indian Express, we stand by this freedom.  
 We celebrate it by being unbiased and independent.  
 And by having a voice that isn't afraid to speak its mind.

#InformYourOpinion

The Indian Express.  
 For the Indian Intelligent.

indianexpress.com

The Indian EXPRESS  
 JOURNALISM OF COURAGE